ViiV HEALTHCARE RANKED #1 FOR 12TH SUCCESSIVE YEAR IN PATIENTVIEW’S ‘CORPORATE REPUTATION OF PHARMA – FROM THE PATIENT PERSPECTIVE 2024 - 2025’ SURVEY
We are proud to have been named as the most reputable pharmaceutical company - for the 12th consecutive year - in PatientView’s ‘Corporate Reputation of Pharma – from the ‘Patient Perspective 2024 - 2025’ survey.
This recognition means so much because it is based on feedback from our partners - from patient groups working directly with us and also those familiar with us and our work. We don’t take this for granted because it represents our commitment to working together across the HIV community to achieve our shared goal of ending the epidemic. Together, we are so much stronger.
We are 100% dedicated to preventing, treating and, ultimately, curing HIV - our mission is to leave no person living with HIV behind. While great progress has been made in science, there is still much to be done. But we are ready for the challenge. We are unwavering in our commitment to partnering with and listening to the HIV community, putting the needs and wants of the those living with HIV and those who could benefit from PrEP at the heart of everything we do. Our work, from the lab to conversations with physicians, is driven by insights from patients, as we constantly look for ways to improve the experience for a person living with HIV or who could benefit from prevention interventions.
We have continued to support community-led organisations through our Positive Action programme, the longest-running corporate funding-based programme dedicated to supporting communities most affected by HIV worldwide. Positive Action partners with community-based organisations that are dedicated to supporting people most impacted by or vulnerable to HIV.
We would like to thank everyone who took the time to participate and share their feedback in the survey. As a HIV community, we are stronger together, and we welcome our responsibility to not only deliver new innovations but also represent those affected by HIV. We look forward to continuing our collaboration with you.
Dr Nneka Nwokolo, Head of Patient Engagement, ViiV Healthcare
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries,email: Audrey Abernathy
OR call +1 919 605 4521
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
